Filing Flows › TriSalus Life Sciences (TLSI) › Q1 2026 › vs Q1 2025
TriSalus Life Sciences (TLSI) Q1 2026 vs Q1 2025 (year over year)
TriSalus Life Sciences's revenue fell $268K (-3%) from $9.2M in Q1 2025 to $8.9M in Q1 2026.
TriSalus Life Sciences, Q1 2026: revenue $8.9M (-3% year over year), operating margin -94.5%, net earnings $1.5M, operating cash flow −$6.5M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.9M | $9.2M | −$268K | -3% |
| Other income, net | $10.0M | −$3.0M | $13.0M | — |
| Costs & expenses | $18.9M | $19.5M | −$689K | -4% |
| Operating costs | $17.3M | $16.5M | $814K | +5% |
| Income tax | $4K | $5K | −$1K | -20% |
| Net earnings | $1.5M | −$10.4M | $11.9M | — |
| Cost of revenue | $1.2M | $1.5M | −$265K | -18% |
| Research & development | $3.2M | $3.0M | $195K | +6% |
| Sales & marketing | $7.4M | $6.7M | $679K | +10% |
| General & admin | $5.5M | $5.2M | $205K | +4% |
| Operating cash sources | $10.6M | −$4.1M | $14.7M | — |
| Depreciation & amortization | $135K | $172K | −$37K | -22% |
| Share-based compensation | $2.5M | $1.6M | $852K | +53% |
| Cash used in operations | $6.5M | $4.5M | $2.0M | +44% |
| Working capital & other | $10.6M | −$4.1M | $14.7M | — |
Questions
How much did TriSalus Life Sciences's revenue grow year over year in Q1 2026?
TriSalus Life Sciences's revenue fell $268K (-3%) from $9.2M in Q1 2025 to $8.9M in Q1 2026.